All In Biotech

Drug Trial Radar · NCT06311786

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants

A Phase 1, Open-Label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of Single Oral Dose [14C]-BIIB091 in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Apr 8, 2024

Primary completion

May 11, 2024

Study completion May 11, 2024

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main goal of this study is to learn how \[14C\]-BIIB091 moves through and is processed by the body and to look at how much of BIIB091's metabolites (what is produced when BIIB091 is broken down by the body) appears in the blood, urine, and stool in healthy male participants. The study will also help researchers learn more about the safety of BIIB091 in healthy male participants.

Conditions

  • Healthy Volunteer

Interventions

  • [14C]-BIIB091Drug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount of BIIB091 Excreted per Sampling Interval in Urine (Aeu)Time frame: Pre-dose and at multiple timepoints up to Day 10
  2. Amount of BIIB091 Excreted per Sampling Interval in Feces (Aef)Time frame: Pre-dose and at multiple timepoints up to Day 10
  3. Cumulative Amount of BIIB091 Excreted per Sampling Interval in Urine (Cum Aeu)Time frame: Pre-dose and at multiple timepoints up to Day 10
  4. Cumulative Amount of BIIB091 Excreted per Sampling Interval in Feces (Cum Aef)Time frame: Pre-dose and at multiple timepoints up to Day 10
  5. Percentage of BIIB091 Excreted per Sampling Interval in Urine (%Feu)Time frame: Pre-dose and at multiple timepoints up to Day 10
  6. Percentage of BIIB091 Excreted per Sampling Interval in Feces (%Fef)Time frame: Pre-dose and at multiple timepoints up to Day 10
  7. Cumulative Percentage of BIIB091 Excreted in Urine (Cum %Feu)Time frame: Pre-dose and at multiple timepoints up to Day 10
  8. Cumulative Percentage of BIIB091 Excreted in Feces (Cum %Fef)Time frame: Pre-dose and at multiple timepoints up to Day 10
  9. Maximum Observed Concentration (Cmax) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
  10. Time to Reach Maximum Observed Concentration (Tmax) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
  11. Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
  12. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
  13. Terminal Half-Life (t1/2) of [14C]-BIIB091-Derived Materials in Plasma and Whole BloodTime frame: Pre-dose and at multiple timepoints up to Day 5
  14. Apparent Clearance (CL/F) of BIIB091 in PlasmaTime frame: Pre-dose and at multiple timepoints up to Day 5
  15. Apparent Volume of Distribution (Vz/F) of BIIB091 in PlasmaTime frame: Pre-dose and at multiple timepoints up to Day 5
  16. Quantitative Profile of [14C]-BIIB091 Metabolites in PlasmaTime frame: Pre-dose and at multiple timepoints up to Day 4
  17. Quantitative Profile of [14C]-BIIB091 Metabolites in UrineTime frame: Pre-dose and at multiple timepoints up to Day 10
  18. Quantitative Profile of [14C]-BIIB091 Metabolites in FecesTime frame: Pre-dose and at multiple timepoints up to Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Clinical Research Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.